Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack

about

Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack

Item

http://www.wikidata.org/entity/Q57055454

description

im Oktober 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack

@en

Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack

@nl

type

Item

label

Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack

@en

Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack

@nl

prefLabel

Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack

@en

Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack

@nl

P1476

Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack

@en

P2093

Carsten Müller-Tidow

http://www.w3.org/2001/XMLSchema#string

Richard F Schlenk

http://www.w3.org/2001/XMLSchema#string

Sonia Jaramillo

http://www.w3.org/2001/XMLSchema#string

P2860

Assessment of Minimal Residual Disease in Standard-Risk AML.

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Relapsed/refractory acute myeloid leukemia: any progress?

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

P304

1579-1581

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3324/HAEMATOL.2018.200485

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2018-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30270203

http://www.w3.org/2001/XMLSchema#string

P921

hematology

leukemia

P932

6165816

http://www.w3.org/2001/XMLSchema#string